Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI

BACKGROUND: Corticosteroids are the mainstay of treatment for immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI), but the optimal duration of therapy has not been established. Prolonged use of corticosteroids can cause numerous adverse effects and may decrease progression-free sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Shruti, Garcia-Carro, Clara, Prosek, Jason M, Glezerman, Ilya, Herrmann, Sandra M, Garcia, Pablo, Abudayyeh, Ala, Lumlertgul, Nuttha, Malik, A Bilal, Loew, Sebastian, Beckerman, Pazit, Renaghan, Amanda D, Carlos, Christopher A, Rashidi, Arash, Mithani, Zain, Deshpande, Priya, Rangarajan, Sunil, Shah, Chintan V, Seigneux, Sophie De, Campedel, Luca, Kitchlu, Abhijat, Shin, Daniel Sanghoon, Coppock, Gaia, Ortiz-Melo, David I, Sprangers, Ben, Aggarwal, Vikram, Benesova, Karolina, Wanchoo, Rimda, Murakami, Naoka, Cortazar, Frank B, Reynolds, Kerry L, Sise, Meghan E, Soler, Maria Jose, Leaf, David E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511654/
https://www.ncbi.nlm.nih.gov/pubmed/36137651
http://dx.doi.org/10.1136/jitc-2022-005646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511654/
https://www.ncbi.nlm.nih.gov/pubmed/36137651
http://dx.doi.org/10.1136/jitc-2022-005646

Ejemplares similares